Skip to main content
Bliss GVS Pharma Limited logo

Bliss GVS Pharma Limited — Investor Relations & Filings

Ticker · BLISSGVS ISIN · INE416D01022 LEI · 335800GXY3YCGGP7KJ45 BSE.NS Manufacturing
Filings indexed 1,237 across all filing types
Latest filing 2025-05-12 Regulatory Filings
Country IN India
Listing BSE.NS BLISSGVS

About Bliss GVS Pharma Limited

https://blissgvs.com/

Bliss GVS Pharma Limited specializes in the development, manufacturing, and marketing of diverse pharmaceutical formulations. The company is a global leader in the production of suppositories and pessaries, maintaining an extensive portfolio within these specialized dosage forms. Its therapeutic focus includes anti-malarials, anti-fungals, anti-bacterials, anti-inflammatories, and gastrointestinal treatments. The organization operates state-of-the-art manufacturing facilities compliant with international quality standards, including WHO-GMP. With a strategic focus on emerging markets, the company distributes its range of prescription and over-the-counter products across Sub-Saharan Africa, Southeast Asia, and Latin America, leveraging a robust supply chain to provide accessible healthcare solutions.

Recent filings

Filing Released Lang Actions
Outcome of Board Meeting
Regulatory Filings
2025-05-12 English
We would like to inform you that, the Board Meeting of the Company was held today i.e. Monday, May 12, 2025 at the registered office of the Company. In pursuant to Regulation 30 and Regulation ....
Regulatory Filings
2025-05-12 English
Issue of Securities
Capital/Financing Update Classification · 95% confidence The document is a formal communication addressed to stock exchanges regarding the outcome of a Board Meeting held on May 12, 2025. It announces the Board's approval for the issuance and allotment of sweat equity shares to two senior executives, including the Managing Director and Vice-President. The document references compliance with SEBI regulations and includes an annexure detailing the issuance. The content is an announcement of a corporate action (share issuance) approved by the Board, not a full financial report or detailed financial statements. The document length is 3555 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as share issuances.
2025-05-12 English
The Board of Directors in its meeting held today i.e., May 12, 2025, has approved the issuance and allotment of Sweat Equity shares to the members of the Promoter and Promoter Group of the Company.
Share Issue/Capital Change Classification · 95% confidence The document is a formal communication addressed to stock exchanges regarding the outcome of a Board Meeting held on May 12, 2025. It announces the Board's approval for the issuance and allotment of sweat equity shares to two senior executives, including the Managing Director and Vice-President. The document includes details of the share issuance but does not contain financial statements or comprehensive financial data. It is an announcement of a corporate action (share issuance) approved by the Board, not a full report or detailed financial disclosure. Therefore, it fits best under the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues or capital changes.
2025-05-12 English
Bliss GVS Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/05/2025 ,inter alia, to consider and approve Update on board meeting- To ....
Board/Management Information Classification · 95% confidence The document is a formal notification addressed to stock exchanges about an upcoming Board Meeting scheduled to consider the issuance of Sweat Equity Shares. It references regulatory compliance under SEBI regulations and the Companies Act, and mentions the closure of the trading window for insiders. The document is an announcement of a future board meeting and does not contain financial data, audit information, or detailed report content. It is not a full report or financial statement but an official communication about a board meeting agenda item related to capital issuance. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the board or senior management.
2025-05-07 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2025-05-07 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.